Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem/Experiment 2
From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-1-15
Curated date: 2023/10/13
Curator: Hodan Issah
Revision editor(s): Hodan Issah, LGeistlinger, Folakunmi
Subjects
- Location of subjects
- France
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Mus musculus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent , Amoxicillin antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent,(2S,5R,6R)-6-,6-(p-hydroxy-alpha-aminophenylacetamido)penicillanic acid,6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)c1ccc(O)cc1)C(O)=O,alpha-amino-p-hydroxybenzylpenicillin,Amolin,Amopenixin,amoxicilina,Amoxicillin anhydrous,amoxicilline,amoxicillinum,amoxycillin,AMPC,AX,C16H19N3O5S,Clamoxyl,InChIKey=LSQZJLSUYDQPKJ-VLWBPTPADT,Moxal,p-hydroxyampicillin,Amoxicillin,amoxicillin
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Mouse before antibiotic treatment
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Mouse after antibiotic treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Mouse sample bacterial results post-antibiotic treatment using amoxicillin-acid clavulanic
- Group 0 sample size Number of subjects in the control (unexposed) group
- 7
- Group 1 sample size Number of subjects in the case (exposed) group
- 12
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- NA
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 2
Reviewed Marked as Reviewed by Folakunmi on 2024-1-15
Source: figure 3D
Description: Amoxicillin/clavulanate acid treatment alters the bacterial microbiota
Abundance in Group 1: increased abundance in Mouse after antibiotic treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Enterobacteriaceae | ||
| Clostridiales vadin BB60Clostridiales vadin BB60 | ||
| Escherichia/Shigella sp. | ||
| Enterococcus |
Revision editor(s): Hodan Issah, Folakunmi
